2022 Volume 28 Issue 2 Pages 170-176
Background: Oxaliplatin is a key drug in the chemotherapy for colorectal cancer, while adverse events by oxaliplatin, such as the sinusoidal injury, may affect the outcome of patients. Recently, splenic volume assessment has been reported to be useful to predict the sinusoidal injury development. The effect of chemotherapy with oxaliplatin are to be clarified in patients following liver resection despite that resection of liver metastasis was shown to improve the outcome of patients with colorectal cancer. Methods: Subjects were 51 patients with colorectal cancer receiving resection of liver metastasis including 29 patients who were given chemotherapy with oxaliplatin following liver resection and 22 patients who were given chemotherapy without oxaliplatin. Splenic volumes were measured after liver resection, at the end of chemotherapy and 1 year later. Results: Among 29 patients receiving chemotherapy with oxaliplatin, splenic volumes were increased in 21 patients (72.4%) at the end of chemotherapy compared to those after liver resection, and the medium volume in 29 patients was 149.6 ml after liver resection and 195.7 ml at the end of chemotherapy (p < 0.001). Enlargement of splenic volumes were also seen 1 year later in 15 of 21 patients (71.4%), and the medium volume in 29 patients was 194.0 ml, which was larger than that after liver resection (p =.005). In contrast, such changes in splenic volumes were absent in patients receiving chemotherapy without oxaliplatin. Conclusion: Considering the change in splenic volumes, the sinusoidal injury might occur in about 70% of patients receiving oxaliplatin following liver resection, and was also seen in about 70% of these patients even 1 year later.
